Breaking News Instant updates and real-time market news.

AST

Asterias

$3.18

-0.02 (-0.63%)

07:02
03/21/17
03/21
07:02
03/21/17
07:02

Asterias provides update on AST-OPC1 SCiSTAR Phase 1/2a clinical study

Asterias Biotherapeutics reported that including the sixth and final patient in the AIS-A 10M cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previously-announced motor function improvements at 6-months following administration of AST-OPC1. "We are excited to see the sixth and final patient in the AIS-A 10 million cell cohort show upper extremity motor function improvement at 3 months and further improvement at 6 months, especially because this particular patient's hand and arm function had actually been deteriorating prior to receiving treatment with AST-OPC1," stated Dr. Edward Wirth III, Chief Medical Officer. "We are very encouraged by the meaningful improvements in the use of arms and hands seen in the SciStar study to date since such gains can increase a patient's ability to function independently following complete cervical spinal cord injuries." The UEMS improvement at 6-months for the final patient was 9 points and in line with the median and average 6-month UEMS improvement for all six patients in this cohort (9.7 average; 9 median). In all six patients, administration of AST-OPC1 was followed by early improvements in UEMS at 3-months that were sustained or further increased through their most recent follow-up assessment. In addition to the motor score gains, the final patient in the AIS-A 10 million cell cohort has so far achieved a one motor level improvement over baseline on both sides of his body. All six patients in this cohort have now achieved at least a one motor level improvement over baseline on at least one side. The trial results to date continue to indicate a positive safety profile for AST-OPC1. There have been no serious adverse events related to AST-OPC1 and data from the study indicate that AST-OPC1 can be safely administered to patients in the subacute period after severe cervical spinal cord injury.

  • 28

    Mar

AST Asterias
$3.18

-0.02 (-0.63%)

04/25/16
RODM
04/25/16
INITIATION
Target $12
RODM
Buy
Asterias initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started Asterias Biotherapeutics with a Buy rating and $12 price target.
05/23/16
CHDN
05/23/16
INITIATION
Target $5.5
CHDN
Buy
Asterias initiated with a Buy at Chardan
Target $5.50.

TODAY'S FREE FLY STORIES

AEL

American Equity

$28.06

0.06 (0.21%)

06:34
07/25/17
07/25
06:34
07/25/17
06:34
Downgrade
American Equity rating change  »

American Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

TRMB

Trimble

$38.20

0.49 (1.30%)

06:34
07/25/17
07/25
06:34
07/25/17
06:34
Hot Stocks
Trimble adds first partner in Latin America to Vantage network »

Trimble announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 02

    Aug

  • 14

    Aug

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Hot Stocks
Supervalu sees FY18 net earnings from continuing operations $51M-$70M »

Sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BIIB

Biogen

$284.70

1.78 (0.63%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Biogen raises FY17 adjusted EPS view to $20.80-$21.40 from $20.45-$21.25 »

FY17 consensus $20.38.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

GPK

Graphic Packaging

$13.77

0.04 (0.29%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Graphic Packaging reports Q2 adj. EPS 15c, consensus 15c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Hot Stocks
Breaking Hot Stocks news story on PulteGroup »

PulteGroup believes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
Supervalu reports Q1 adjusted EPS 9c, consensus 11c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MORE

Monogram Residential Trust

$11.95

0.01 (0.08%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Downgrade
Monogram Residential Trust rating change  »

Monogram Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
PulteGroup reports Q2 adjusted EPS 47c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TEAM

Atlassian

$36.41

0.66 (1.85%)

06:31
07/25/17
07/25
06:31
07/25/17
06:31
Upgrade
Atlassian rating change  »

Atlassian upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

BIIB

Biogen

$284.70

1.78 (0.63%)

06:31
07/25/17
07/25
06:31
07/25/17
06:31
Earnings
Biogen reports Q2 adjusted EPS $5.04, consensus $4.41 »

Reports Q2 revenue $3.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

GOOG

Alphabet

$980.34

7.42 (0.76%)

, GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

06:30
07/25/17
07/25
06:30
07/25/17
06:30
Recommendations
Alphabet, Alphabet Class A analyst commentary  »

Alphabet earnings…

GOOG

Alphabet

$980.34

7.42 (0.76%)

GOOGL

Alphabet Class A

$998.31

4.47 (0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:30
07/25/17
07/25
06:30
07/25/17
06:30
Hot Stocks
Eli Lilly will pursue new standard-of-care changing therapies in oncology »

Eli Lilly is providing an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:29
07/25/17
07/25
06:29
07/25/17
06:29
Earnings
Eli Lilly raises FY17 EPS view to $4.10-$4.20 from $4.05-$4.15, consensus $4.12 »

Raises FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

, BMWYY

BMW

$30.72

-0.8 (-2.54%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Periodicals
Daimler directors to discuss alleged German auto cartel, Reuters says »

Daimler's (DDAIF)…

DDAIF

Daimler AG

$71.00

-1.9399 (-2.66%)

BMWYY

BMW

$30.72

-0.8 (-2.54%)

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

POAHY

Porsche

$5.82

-0.03 (-0.51%)

AUDVF

Audi AG

$835.60

-4.8 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

$29.20

-0.35 (-1.18%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Upgrade
Werner rating change  »

Werner upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

TNTR

Tintri

$6.95

0.16 (2.36%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Initiation
Tintri initiated  »

Tintri initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BY

Byline Bancorp

$20.85

0.13 (0.63%)

06:28
07/25/17
07/25
06:28
07/25/17
06:28
Initiation
Byline Bancorp initiated  »

Byline Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:26
07/25/17
07/25
06:26
07/25/17
06:26
Earnings
Eli Lilly reports Q2 EPS $1.11, consensus $1.05 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

NCMGY

Newcrest Mining

$15.72

0.12 (0.77%)

06:26
07/25/17
07/25
06:26
07/25/17
06:26
Upgrade
Newcrest Mining rating change  »

Newcrest Mining upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPNC

Spectranetics

$38.50

0.05 (0.13%)

06:21
07/25/17
07/25
06:21
07/25/17
06:21
Downgrade
Spectranetics rating change  »

Spectranetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMP

Tompkins Financial

$78.41

-0.14 (-0.18%)

06:21
07/25/17
07/25
06:21
07/25/17
06:21
Upgrade
Tompkins Financial rating change  »

Tompkins Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$40.61

-0.2 (-0.49%)

, AAPL

Apple

$152.09

1.82 (1.21%)

06:20
07/25/17
07/25
06:20
07/25/17
06:20
Periodicals
Sony restructures television production unit, WSJ reports »

Sony Pictures…

SNE

Sony

$40.61

-0.2 (-0.49%)

AAPL

Apple

$152.09

1.82 (1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

LLY

Eli Lilly

$84.74

0.08 (0.09%)

, INCY

Incyte

$138.27

4.05 (3.02%)

06:20
07/25/17
07/25
06:20
07/25/17
06:20
Hot Stocks
Eli Lilly, Incyte resubmit baricitinib NDA to FDA »

Eli Lilly (LLY) and…

LLY

Eli Lilly

$84.74

0.08 (0.09%)

INCY

Incyte

$138.27

4.05 (3.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 11

    Sep

SSB

South State

$83.90

0.7 (0.84%)

06:19
07/25/17
07/25
06:19
07/25/17
06:19
Upgrade
South State rating change  »

South State upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 18

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.